

# Eric Padron

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4649395/publications.pdf>

Version: 2024-02-01

137  
papers

5,665  
citations

136740

32  
h-index

91712

69  
g-index

144  
all docs

144  
docs citations

144  
times ranked

5363  
citing authors

#	ARTICLE	IF	CITATIONS
1	Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts. <i>Leukemia</i> , 2022, 36, 1189-1192.	3.3	5
2	Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e467-e476.	0.2	5
3	Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients. <i>Blood Cancer Journal</i> , 2022, 12, 26.	2.8	5
4	&lt;i>SF3B1&lt;/i>-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity. <i>Haematologica</i> , 2022, 107, 1189-1192.	1.7	3
5	Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2022, 36, 1693-1696.	3.3	1
6	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. <i>Leukemia</i> , 2022, 36, 1703-1719.	3.3	1,211
7	Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). <i>Leukemia</i> , 2021, 35, 1145-1155.	3.3	27
8	Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. <i>Lancet Haematology</i> , 2021, 8, e135-e148.	2.2	32
9	Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 247-255.	1.2	5
10	Chronic myelomonocytic leukemia diagnosis and management. <i>Leukemia</i> , 2021, 35, 1552-1562.	3.3	18
11	<i>CBL</i> mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1. <i>Blood</i> , 2021, 137, 2209-2220.	0.6	18
12	Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted. <i>Leukemia</i> , 2021, 35, 3329-3333.	3.3	6
13	Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021, 39, 1584-1594.	0.8	278
14	RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. <i>Nature Communications</i> , 2021, 12, 2901.	5.8	44
15	Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2021, 35, 2739-2751.	3.3	10
16	Cytokine-like protein 1&quot;induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML. <i>Blood</i> , 2021, 137, 3390-3402.	0.6	16
17	Validation of the international working group proposal for <i>SF3B1</i> mutant myelodysplastic syndromes. <i>Blood</i> , 2021, 138, 989-992.	0.6	7
18	Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 6095-6105.	3.2	14

#	ARTICLE	IF	CITATIONS
19	Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021, 39, 3737-3746.	0.8	90
20	Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy. <i>Leukemia Research</i> , 2021, 109, 106640.	0.4	7
21	MYC Overexpression is Associated with an Early Disease Progression from MDS to AML. <i>Leukemia Research</i> , 2021, 111, 106733.	0.4	6
22	It is time to shift the treatment paradigm in myelodysplastic syndromes: A focus on novel developments and current investigational approaches exploring combinatorial therapy in high-risk MDS. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101325.	0.7	4
23	Abnormal monocyte differentiation and function in chronic myelomonocytic leukemia. <i>Current Opinion in Hematology</i> , 2021, Publish Ahead of Print, 20-26.	1.2	0
24	Mutations Highly Specific for Secondary AML Are Associated with Poor Outcomes in Patients with NPM1-Mutated ELN Favorable Risk AML. <i>Blood</i> , 2021, 138, 686-686.	0.6	3
25	Gender Disparities in Myelodysplastic Syndromes: Phenotype, Genotype, and Outcomes. <i>Blood</i> , 2021, 138, 1984-1984.	0.6	0
26	Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. <i>Leukemia</i> , 2020, 34, 656-661.	3.3	32
27	Moving towards a uniform risk stratification system in CMML - How far are we?. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101131.	0.7	2
28	Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)â€”a study of 1084 patients. <i>Leukemia</i> , 2020, 34, 1407-1421.	3.3	68
29	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> , 2020, 7, e601-e612.	2.2	56
30	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. <i>Nature Genetics</i> , 2020, 52, 1219-1226.	9.4	367
31	Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. <i>Blood Advances</i> , 2020, 4, 2866-2870.	2.5	81
32	Molecular genetics of MDS/MPN overlap syndromes. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101195.	0.7	7
33	Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes. <i>Leukemia and Lymphoma</i> , 2020, 61, 1418-1427.	0.6	16
34	Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the <scp>SARSâ€CoV</scp>â€2 pandemic. <i>American Journal of Hematology</i> , 2020, 95, E203-E208.	2.0	10
35	Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. <i>Leukemia Research</i> , 2020, 93, 106367.	0.4	15
36	Patient-Reported Outcomes and Frailty Among Participants in the NHLBI MDS Natural History Study. <i>Blood</i> , 2020, 136, 15-16.	0.6	2

#	ARTICLE	IF	CITATIONS
37	A Phase 1/1b Safety Study of Prgn-3006 Ultracar-Tâ„¢ in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome. <i>Blood</i> , 2020, 136, 17-17.	0.6	4
38	Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS. <i>Blood</i> , 2020, 136, 32-33.	0.6	2
39	Phase 1 study of lenzilumab, a recombinant anti-â€œhuman GM-CSF antibody, for chronic myelomonocytic leukemia. <i>Blood</i> , 2020, 136, 909-913.	0.6	36
40	Hematopoiesis and Aging. , 2020, , 305-328.		0
41	SF3B1 Splicing Mutation in the Context of Therapy Related MDS. <i>Blood</i> , 2020, 136, 31-32.	0.6	0
42	SF3B1 Mutations and Not TP53 Are Associated with Poor Outcomes in Patients with Del(5q) Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2020, 136, 25-26.	0.6	0
43	High MYC Protein Expression in MDS Is Associated with Early Transformation to AML. <i>Blood</i> , 2020, 136, 39-40.	0.6	0
44	Acquisition of IDH2 Mutations in Relapsed/Refractory AML Is Associated with Worse Patient Outcomes. <i>Blood</i> , 2020, 136, 19-20.	0.6	0
45	Characteristics of Different Splicing Factor Mutation Hotspots in Myelofibrosis. <i>Blood</i> , 2020, 136, 37-37.	0.6	1
46	Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. <i>Leukemia</i> , 2019, 33, 205-216.	3.3	39
47	Non-canonical transcriptional consequences of BET inhibition in cancer. <i>Pharmacological Research</i> , 2019, 150, 104508.	3.1	7
48	Leveraging Single-Cell RNA Sequencing Experiments to Model Intratumor Heterogeneity. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-10.	1.0	16
49	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. <i>Haematologica</i> , 2019, 104, 1935-1949.	1.7	93
50	Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2019, 33, 2466-2480.	3.3	66
51	Managing Clonal Hematopoiesis in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 7-11.	0.8	60
52	A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS). <i>Leukemia Research</i> , 2019, 81, 56-61.	0.4	20
53	TP53 and therapy-related myeloid neoplasms. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 98-103.	0.7	9
54	Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 543-549.	1.2	2

#	ARTICLE	IF	CITATIONS
55	Downregulating Notch counteracts KrasG12D-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm. <i>Leukemia</i> , 2019, 33, 671-685.	3.3	12
56	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. <i>Leukemia</i> , 2019, 33, 1747-1758.	3.3	195
57	Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group. <i>Blood</i> , 2019, 134, 844-844.	0.6	3
58	Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Group and the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2019, 134, 4581-4581.	0.6	3
59	Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms. <i>Blood</i> , 2019, 134, 4238-4238.	0.6	2
60	CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<math>\leq 60</math> Years Old) Compared to Older Patients (<math>\geq 60</math> Years Old) with Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 3894-3894.	0.6	3
61	Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients <math>\geq 70</math> Years with Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1368-1368.	0.6	3
62	CSF3R Mutations Are Exceedingly Rare Genetic Events Associated with Inferior Survival and Sensitivity to Ruxolitinib across Myeloid Malignancies. <i>Blood</i> , 2019, 134, 4167-4167.	0.6	2
63	Abnl Marro: An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes. <i>Blood</i> , 2019, 134, 4273-4273.	0.6	2
64	Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 676-676.	0.6	59
65	WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State. <i>Blood</i> , 2019, 134, 1717-1717.	0.6	4
66	A Phase 1 Study of Lenzilumab, a humanized recombinant Anti-Human Granulocyte-Macrophage Colony-Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2019, 134, 4234-4234.	0.6	4
67	Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 149-149.	0.6	9
68	Effects of <i>Corynebacterium bovis</i> on Engraftment of Patient-derived Chronic-Myelomonocytic Leukemia Cells in NSGS Mice. <i>Comparative Medicine</i> , 2019, 69, 276-282.	0.4	12
69	Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a. <i>Blood</i> , 2019, 134, 4220-4220.	0.6	1
70	Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2636-2636.	0.6	0
71	Genetic and Clinical Features of Chronic Myelomonocytic Leukemia with Fibrosis. <i>Blood</i> , 2019, 134, 5442-5442.	0.6	0
72	Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes. <i>Blood</i> , 2019, 134, 4177-4177.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome. <i>Blood</i> , 2019, 134, 4621-4621.	0.6	0
74	Bone Marrow Mastocytosis Is Independently Associated with Inferior Survival in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2019, 134, 2956-2956.	0.6	0
75	RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 2052-2052.	0.6	0
76	Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study. <i>Blood</i> , 2019, 134, 4271-4271.	0.6	0
77	H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. <i>Nature Medicine</i> , 2018, 24, 497-504.	15.2	391
78	Between a rock and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. <i>Annals of Hematology</i> , 2018, 97, 435-441.	0.8	95
79	Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults. <i>HemaSphere</i> , 2018, 2, e150.	1.2	91
80	Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia. <i>Current Treatment Options in Oncology</i> , 2018, 19, 67.	1.3	26
81	Genetic Landscape of Acute Myeloid Leukemia Interrogated by Next-generation Sequencing: A Large Cancer Center Experience. <i>Cancer Genomics and Proteomics</i> , 2018, 15, 121-126.	1.0	23
82	Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. <i>EBioMedicine</i> , 2018, 31, 174-181.	2.7	72
83	Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays. <i>Clinical Cancer Research</i> , 2018, 24, 5918-5924.	3.2	84
84	Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival. <i>Blood</i> , 2018, 132, 1817-1817.	0.6	10
85	Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2741-2741.	0.6	5
86	Comparison of Induction Strategies and Responses for Acute Myeloid Leukemia Patients after Resistance to Hypomethylating Agents for Antecedent Myeloid Malignancy. <i>Blood</i> , 2018, 132, 665-665.	0.6	5
87	Leukocytosis Is Associated with End Organ Damage in Chronic Myelomonocytic Leukemia (CMML) and Can be Mitigated with Cytoreductive Therapy. <i>Blood</i> , 2018, 132, 3109-3109.	0.6	2
88	Hematopoiesis and Aging. , 2018, , 1-24.		0
89	Prognostic Impact of MYC Oncoprotein Expression on Survival Outcome in Secondary AML Patients. <i>Blood</i> , 2018, 132, 2756-2756.	0.6	0
90	Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis. <i>Blood</i> , 2017, 129, 1881-1883.	0.6	54

#	ARTICLE	IF	CITATIONS
91	Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. <i>Lancet Oncology</i> , The, 2017, 18, 112-121.	5.1	249
92	Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. <i>Blood</i> , 2017, 130, 397-407.	0.6	112
93	Myelodysplasia in younger adults: outlier or unique molecular entity?. <i>Haematologica</i> , 2017, 102, 967-968.	1.7	5
94	p53 synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia. <i>Blood</i> , 2017, 129, 358-370.	0.6	29
95	Emerging Therapies and Clinical Challenges in Chronic Myelomonocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S85-S87.	0.2	0
96	The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e45-e53.	0.2	13
97	ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS. <i>Blood Cancer Journal</i> , 2017, 7, 633.	2.8	19
98	TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 753-758.	0.2	18
99	Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 7-13.	0.2	5
100	Chipping in on clonal hematopoiesis. <i>Oncotarget</i> , 2017, 8, 84637-84638.	0.8	1
101	Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. <i>Cancer Biology and Medicine</i> , 2016, 13, 360-372.	1.4	13
102	When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia. <i>Blood</i> , 2016, 128, 2381-2387.	0.6	51
103	Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S64-S66.	0.2	28
104	An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 425-433.	1.2	18
105	Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide. <i>Cancer Medicine</i> , 2016, 5, 1694-1701.	1.3	5
106	Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. <i>Nature Communications</i> , 2016, 7, 10767.	5.8	177
107	Integrating mutation variant allele frequency into clinical practice in myeloid malignancies. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2016, 9, 89-95.	0.6	37
108	A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). <i>Clinical Cancer Research</i> , 2016, 22, 3746-3754.	3.2	84



#	ARTICLE	IF	CITATIONS
109	H3B-8800, an Orally Bioavailable Modulator of the SF3b Complex, Shows Efficacy in Spliceosome-Mutant Myeloid Malignancies. <i>Blood</i> , 2016, 128, 966-966.	0.6	27
110	Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes?. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 349-354.	0.9	9
111	An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. <i>Blood</i> , 2015, 125, 1857-1865.	0.6	153
112	Detection of a PDGFRB fusion in refractory CMML without eosinophilia: A case for broad spectrum tumor profiling. <i>Leukemia Research Reports</i> , 2015, 4, 70-71.	0.2	9
113	Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms: An Update on Risk Stratification, Molecular Genetics, and Therapeutic Approaches Including Allogeneic Hematopoietic Stem Cell Transplantation. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, . . e398-e412.	1.8	11
114	Second Myeloid Malignancies in a Large Cohort of Patients With Chronic Lymphocytic Leukemia: A Single Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S14-S18.	0.2	7
115	Outcome of patients with low-risk and intermediate-risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium. <i>Cancer</i> , 2015, 121, 876-882.	2.0	93
116	Cutting the cord from myelodysplastic syndromes. <i>Current Opinion in Hematology</i> , 2015, 22, 163-170.	1.2	22
117	A Close Association of Autoimmune-Mediated Processes and Autoimmune Disorders with Chronic Myelomonocytic Leukemia: Observation from a Single Institution. <i>Acta Haematologica</i> , 2015, 133, 249-256.	0.7	44
118	An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. <i>Haematologica</i> , 2015, 100, 1117-1130.	1.7	97
119	Transformation of the Clinical Management of CMML Patients Through In-Depth Molecular Characterization. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S50-S55.	0.2	2
120	Pacritinib (PAC) Synergistically Potentiates Azacitidine (5AZA) Cytotoxicity in Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2015, 126, 1658-1658.	0.6	10
121	Lenalidomide Induces Lipid Raft Assembly to Enhance Erythropoietin Receptor Signaling in Myelodysplastic Syndrome Progenitors. <i>PLoS ONE</i> , 2014, 9, e114249.	1.1	29
122	ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. <i>Blood</i> , 2014, 123, 3675-3677.	0.6	22
123	An International Data Set for the Study of Chronic Myelomonocytic Leukemia (CMML) Validates Modern Prognostic Scoring Systems and Demonstrates a Critical Need for Novel Prognostication Strategies. <i>Blood</i> , 2014, 124, 530-530.	0.6	4
124	The clinical management of chronic myelomonocytic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 172-8.	0.3	14
125	Deletion 5q MDS: Molecular and therapeutic implications. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 365-375.	0.7	44
126	GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. <i>Blood</i> , 2013, 121, 5068-5077.	0.6	137



#	ARTICLE	IF	CITATIONS
127	A Comparison of Prognostic Models for Chronic Myelomonocytic Leukemia (CMML) in the Era of Hypomethylating Agents. <i>Blood</i> , 2012, 120, 1695-1695.	0.6	2
128	A Close Association of History of Autoimmunity with Chronic Myelomonocytic Leukemia (CMML) in Contrast to Chronic Myelogenous Leukemia (CML). <i>Blood</i> , 2012, 120, 1712-1712.	0.6	6
129	Validation of the Revised International Prognostic Scoring System (R-IPSS) for Patients with Myelodysplastic Syndromes: Therapeutic Implications.. <i>Blood</i> , 2012, 120, 2816-2816.	0.6	4
130	Validation of the Lower Risk MD Anderson Prognostic Scoring System for Patients with Myelodysplastic Syndromes. <i>Blood</i> , 2012, 120, 3826-3826.	0.6	1
131	Azacitidine Treatment for Lenalidomide (LEN)-Resistant Myelodysplastic Syndrome (MDS) with Del 5q. <i>Blood</i> , 2012, 120, 3833-3833.	0.6	7
132	Evidence for Selective Benefit of Sequential Treatment with Azanucleosides in Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2012, 120, 4937-4937.	0.6	2
133	Outcome of Patients with Lower-Risk Myelodysplastic Syndrome (MDS) After Azacitidine (AZA) Treatment Failure.. <i>Blood</i> , 2012, 120, 2815-2815.	0.6	0
134	The Utility of New Prognostic Models in Lower Risk MDS to Identify Patients Who Drive Survival Advantage From Disease Altering Treatment Modalities. <i>Blood</i> , 2012, 120, 3852-3852.	0.6	0
135	Outcomes in Patients with Acute Myeloid Leukemia Preceded by Breast Cancer. <i>Blood</i> , 2012, 120, 4316-4316.	0.6	0
136	Biology and treatment of the 5q- syndrome. <i>Expert Review of Hematology</i> , 2011, 4, 61-69.	1.0	23
137	The 5q- Syndrome: Biology and Treatment. <i>Current Treatment Options in Oncology</i> , 2011, 12, 354-368.	1.3	11